{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"The proportion of response-evaluable patients experiencing OHR will be estimated, with a 95% exact binomial confidence interval. Overall hematologic response rate as defined by normalization of the free light chain levels and ratio, negative serum and urine immunofixation OR reduction in the difference between involved and uninvolved free light chains (dFLC) to \\<4 mg/dL.","groups":[{"description":"Subjects with AL will receive Bendamustine and Dexamethasone\n\nBendamustine: Patients will start bendamustine at dose level 0 and according to CrCl on day 1 and 2 of each cycle:\n\n* CrCl ≥ 60 mL/min: 100 mg/m2 IV on day 1 and 2 of each cycle\n* CrCl 59 - 30 mL/min: 90 mg/m2 IV on day 1 and 2 of each cycle\n\nAvailable to qualifying subjects is the option to dose escalate to dose level (+)1:\n\n* 120 mg/m2 (if CrCl ≥ 60 mL/min at the time of inclusion into the study)\n* 100 mg/m2 (if CrCl 59-30 mL/min at the time of inclusion into the study)\n\nDexamethasone: 40 mg orally on days 1, 8, 15, 22 of each cycle","id":"OG000","title":"Treatment Arm"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Overall Hematologic Response Rate (OHR)","type":"SECONDARY","unitOfMeasure":"Participants"}